KNSA FY 2023 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena

KNSAKiniksa Pharmaceuticals, Ltd.

$3B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$270M+22.7% YoY

Gross Profit

$214M79.1% margin

Operating Income

-$25M-9.3% margin

Net Income

$14M5.2% margin

EPS (Diluted)

$0.20

Cash Flow

Operating Cash Flow

$13M

Free Cash Flow

$13M

Stock-Based Comp.

$27M

Balance Sheet

Total Assets

$526M

Total Liabilities

$87M

Stockholders' Equity

$439M

Cash & Equivalents

$108M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$270M	$220M	+22.7%
Gross Profit	$214M	$197M	+8.3%
Operating Income	-$25M	$10M	-357.8%
Net Income	$14M	$183M	-92.3%